The Siemens Bayer Advia 120 Hematology Analyzer offers a unique portfolio of diagnostic assays and gold-standard flow cytometry testing. To satisfy the demands of laboratories, Siemens delivers a hematology analyzer with comprehensive testing parameters, flexible sample handling, a user-defined interface, and a compact bench-top design. The ADVIA 120 Hematology System can automate your hematology lab without the need for large track-based systems or reflexive testing. This is how Siemens delivers practical solutions to your hematology lab. Streamline workflow and maximize productivity with a hematology analyzer that eliminates the majority of commonly performed manual steps. The ADVIA 120 System delivers the gold-standard in testing methodology for optimum results while offering the simplicity and flexibility you need for easy integration into your lab. ADVIA technology utilizes peroxidase staining—the gold-standard in differential testing. This primary methodology of the ADVIA Hematology Systems also provides a secondary total white cell count that acts as an inteal QC check to monitor sample integrity.

Features :

• Automates hematology workflow without the need for large track-based systems or reflexive testing
• Maximizes efficiency through user-defined screen configurations and reports
• Simplifies maintenance with Unifluidics^™ Technology through reduced fluidics, elimination of pinch valves, and automated daily cleaning
• Streamlines productivity with a 150 capacity rack-based autosampler, allowing 75 minutes of true walk-away time
• Reduces the need for manual slide production and review by utilizing WBC and RBC/PLT technology and high specificity
• Maximizes the effectiveness of costly platelet transfusions with accurate results the first time—even at very low platelet levels
• Unique cytochemical differentiation of myeloid and lymphoid cells, and six-parameter differential supplies additional clinical information
• Direct measurements of intracellular hemoglobin provide sensitive and specific RBC morphology for the accurate and early indication of disease states
• Accurate platelet counts in the clinically significant range (excluding microcytic red cells and cell fragments) minimize the number of manual counts and unnecessary costly platelet transfusions
• Further isolate and identify disease states without additional labor through CSF and CHr testing capabilities